Sarepta Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $611,091 | $744,856 | $658,412 | $467,172 |
Gross Profit | 447,693 | 607,292 | 526,108 | 375,481 |
EBITDA | 173,728 | -369,037 | 190,551 | 48,730 |
EBIT | 158,866 | -379,015 | 176,218 | 38,924 |
Net Income | 196,892 | -447,508 | 159,049 | 33,611 |
Net Change In Cash | 611,091 | 744,856 | 658,412 | 467,172 |
Free Cash Flow | 231,779 | -629,326 | 53,964 | -97,962 |
Cash | 510,598 | 240,867 | 1,103,010 | 197,855 |
Basic Shares | 106,623 | 97,362 | 108,474 | 100,448 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $1,901,979 | $1,243,336 | $933,013 | $701,887 |
Gross Profit | 1,582,880 | 1,092,993 | 793,024 | 604,838 |
EBITDA | 333,056 | -439,196 | -582,116 | -306,081 |
EBIT | 279,165 | -498,088 | -636,715 | -355,423 |
Net Income | 235,239 | -535,977 | -703,488 | -418,780 |
Net Change In Cash | 1,901,979 | 1,243,336 | 933,013 | 701,887 |
Cost of Revenue | 613,810 | |||
Free Cash Flow | -342,743 | -588,338 | -356,170 | -481,662 |
Cash | 1,103,010 | 428,430 | 966,777 | 2,115,869 |
Basic Shares | 107,875 | 92,398 | 87,559 | 81,262 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | $0 |
2025-06-30 | $2.02 |
2025-03-31 | -$3.42 |
2024-12-31 | $1.90 |
